Oxford Biomedica (otc) (GB:OXB) has released an update.
Oxford Biomedica PLC reports significant growth in contracted client orders and business development pipeline for the fiscal year 2023, with over 50% increases in both categories. Dr. Frank Mathias, CEO, is steering the company’s transformation into a leading global cell and gene therapy CDMO. Despite a challenging year with a one-off impairment charge to the US business, Oxford Biomedica remains optimistic about future profitability, supported by strong demand for its CDMO services and the strategic acquisition of ABL Europe.
For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.